Company profile

Carrick Therapeutics Limited

Privately held: no public share price (Dublin/Boston oncology biopharma; privately held through a Series C round (~$245M total raised; investors include ARCH Venture Partners and a direct Pfizer investment). Not present in the company roster. Sources: https://clinicaltrials.gov/study/NCT05963984 ; https://www.carricktherapeutics.com/news-media/press-releases/detail/17/carrick-therapeutics-closes-series-c-financing ; https://www.crunchbase.com/organization/carrick-therapeutics Entity resolved by asset-pipeline-v2.)

Assets

(1 total)

1Total Assets

0Approved

0Phase 3 / Filed

1Phase 1–2 / Early

1Diseases

Showing 1 of 1 assets

		Target & Modality
Samuraciclib	Phase 2	CDK7Small molecule	HR+/HER2- Breast Cancer HR+/HER2- Metastatic Breast Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.